Lupin Limited Disrupts U.S. Oncology Market with Launch of Generic Dasatinib

Global pharmaceutical powerhouse Lupin Limited has officially announced the U.S. launch of Dasatinib Tablets, a move that significantly strengthens its specialized oncology portfolio. This launch follows the final approval of Lupin’s Abbreviated New Drug Application (ANDA) by the U.S. FDA and was achieved through a strategic development partnership with Canada’s Pharmascience Inc.

The launch targets a lucrative market; as of October 2025, the brand-name reference drug, Sprycel® (marketed by Bristol-Myers Squibb), recorded estimated annual sales of $930 million in the United States.

Product Profile and Bioequivalence

Lupin’s Dasatinib is a direct generic equivalent to Sprycel®, designed to provide the same safety, quality, and therapeutic efficacy at a more accessible price point. The tablets have been launched in six distinct strengths to accommodate varied dosing requirements:

Strengths: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

Therapeutic Indications

Dasatinib is a potent tyrosine kinase inhibitor (TKI) used to treat several aggressive forms of blood cancer:

Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML): For newly diagnosed adults in the chronic phase, as well as those resistant or intolerant to prior treatments (like imatinib).
Ph+ Acute Lymphoblastic Leukemia (ALL): For adults with resistance or intolerance to previous therapies.
Pediatric Use: Indicated for children (1 year and older) with chronic phase Ph+ CML or newly diagnosed Ph+ ALL (in combination with chemotherapy).

Strategic Growth & Market Context

This launch is a centerpiece of Lupin’s 2026 growth strategy, which prioritizes complex generics and specialty medicines.

Production Powerhouse: The launch is bolstered by Lupin’s recent infrastructure expansion, specifically the Vizag Oncology Block commissioned in late 2025. This 4,270-square-meter facility is dedicated to High Potent Active Pharmaceutical Ingredients (HPAPIs).
Dual-Track Strategy: On the same day as this launch, Lupin also announced a partnership with the TB Alliance to develop Telacebec, highlighting a balanced focus on high-margin U.S. generics and global health initiatives.
Financial Impact: Despite the positive product news, Lupin’s stock saw a slight intraday dip of 2.5% on the NSE today, trading around ₹2,084, as investors balanced the launch news with broader market volatility and news of the TB drug collaboration.

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation-led global pharmaceutical leader. The company operates 15 manufacturing sites and 7 research centers worldwide, maintaining a presence in over 100 markets. Its core strengths lie in respiratory, cardiovascular, anti-diabetic, and central nervous system therapies.